Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies
Author: Chi Hin Cho,Tao Hu
Publsiher: Academic Press
Total Pages: 240
Release: 2020-06-22
ISBN 10: 0128199377
ISBN 13: 9780128199374
Language: EN, FR, DE, ES & NL

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies Book Review:

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies
Author: Chi Hin Cho,Tao Hu
Publsiher: Academic Press
Total Pages: 240
Release: 2020-05-24
ISBN 10: 0128199385
ISBN 13: 9780128199381
Language: EN, FR, DE, ES & NL

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies Book Review:

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Investigation of Mechanisms of Drug Resistance in Colorectal Cancer

Investigation of Mechanisms of Drug Resistance in Colorectal Cancer
Author: M. Ortega Duran
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1063739318
Language: EN, FR, DE, ES & NL

Investigation of Mechanisms of Drug Resistance in Colorectal Cancer Book Review:

Colorectal Cancer

Colorectal Cancer
Author: Jindong Chen
Publsiher: BoD – Books on Demand
Total Pages: 128
Release: 2018-05-16
ISBN 10: 1789231000
ISBN 13: 9781789231007
Language: EN, FR, DE, ES & NL

Colorectal Cancer Book Review:

With international experts sharing their experience and knowledge on these different aspects in the management of colorectal cancer, this book has this opportunity to offer all physicians treating colorectal cancer, as well as researchers, updated information concerning the biology, diagnosis, screening, and treatment of colorectal carcinoma. This book provides a detailed evaluation of diagnostic modalities, in-depth analysis of screening for colorectal cancer, recent advances in treatment, and principles and trends in the management of colorectal cancer. This updated knowledge will be an interesting and informative read for any clinician involved in the management of patients with colorectal cancer. In addition, readers such as related physicians, researchers, and colorectal cancer patients are potential beneficiaries of this book.

Notch Signaling Mediates Drug Resistance in Colorectal Cancer Cells Via Effects on DNA Repair Proteins

Notch Signaling Mediates Drug Resistance in Colorectal Cancer Cells Via Effects on DNA Repair Proteins
Author: Dennis George
Publsiher: Unknown
Total Pages: 79
Release: 2016
ISBN 10: 1928374650XXX
ISBN 13: OCLC:957491596
Language: EN, FR, DE, ES & NL

Notch Signaling Mediates Drug Resistance in Colorectal Cancer Cells Via Effects on DNA Repair Proteins Book Review:

Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States and the third most commonly diagnosed cancer in men and women. Despite tremendous progress in diagnosis, prevention, and treatment efforts, tumor recurrence and chemoresistance remain as considerable challenges. Treatment options are limited if surgery and chemotherapy are unsuccessful. Several studies have implicated the Notch signaling pathway in conferring drug resistance to tumor cells, in addition to increased CRC aggressiveness and potential for metastatic spread. Our group previously showed that Notch-1 signaling is highly associated with promoting cancer stem cell properties in CRC cells. Furthermore, we have also confirmed that human colon tissue samples isolated from CRC patients indicate higher expression of DNA repair proteins associated with Base Excision Repair (BER). Herein, we hypothesized that Notch signaling confers drug resistance to tumor cells via signaling effects on critical proteins associated with DNA repair. Methods: The experiments conducted in this study utilized the colon cancer cell line HCT-116. These cells were transduced with an IRES-GFP retrovirus expressing human intracytoplasmic domain of Notch-1 (ICN1). Another group of HCT-116 cells was transduced with a small hairpin mRNA construct (sh59) that effectively knocked out Notch-1 action. Cell lines were exposed to varying concentrations of cytarabine and cisplatin, potent DNA damaging agents, and observed for chemosensitivity. Western blot analysis was performed using standard methodology. Results: Small hairpin mRNA (sh59) transduction into the colon tumor cell line HCT-116 resulted in a significantly decreased expression of critical BER DNA repair enzymes, Poly (ADP-Ribose) Polymerase 1 (PARP1) and 8-Oxoguanine glycosylase (OGG1). These changes were accompanied by significantly higher chemosensitivity of these cells to cytarabine and cisplatin treatment as opposed to cells expressing constitutively active Notch-1 signaling. Furthermore, cells with intact Notch signaling expressed upto two-fold increase in expression of APE1 following treatment with cytarabine compared to cells with no Notch-1 expression. Conclusions: These data indicate a key role for Notch signaling in conferring drug resistance to CRC cells via effects on critical proteins of DNA repair. This finding highlights the potential use of Notch-1 inhibitors in combination with PARP1 inhibitors to effectively target highly drug resistant CRC cells.

Identification of Novel MiRNAs Contributing to Drug Resistance in Colorectal Cancer

Identification of Novel MiRNAs Contributing to Drug Resistance in Colorectal Cancer
Author: Yang Zang
Publsiher: Unknown
Total Pages: 346
Release: 2015
ISBN 10: 1928374650XXX
ISBN 13: OCLC:968205469
Language: EN, FR, DE, ES & NL

Identification of Novel MiRNAs Contributing to Drug Resistance in Colorectal Cancer Book Review:

Colorectal cancer is the third most common diagnosed and the second leading lethal cancer in the United States. Development of drug resistance is one of the primary causes of colorectal cancer relapse yet underlying mechanisms is still largely unknown and therapeutic treatments remain limited. Here we show that expression of miR-520g/miR-587 is correlated with drug resistance of colon cancer cells. Ectopic expression of miR-520g/miR-587 confers resistance to 5-FU or oxaliplatin-induced apoptosis in vitro and attenuates the potency of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo. Further studies indicate that miR-520g mediates drug resistance through down-regulation of p21 expression. Moreover, p53 suppresses miR-520g expression. Inhibition of miR-520g in p53 -/- cells increases their sensitivity to 5-FU treatment. On the other hand, MiR-587 modulates drug resistance through down-regulation of expression of PPP2R1B, which is a direct target of miR-587. Knockdown of PPP2R1B up-regulates pAKT (T308) and XIAP expression, enhancing resistance to 5-FU in colorectal cancer cells, whereas rescue of PPP2R1B in MiR-587 expressing cells decreases pAKT(308) and XIAP expression and re-sensitizes the cells to 5-FU treatment. An AKT inhibitor MK2206 significantly reduces pAKT(T308) and XIAP expression in MiR-587 expressing cells, neutralizing the resistance of the cells to 5-FU cytotoxicity. In addition, inhibition of miR-587 in colon cancer cells increases their sensitivity to 5-FU treatment through the PPP2R1B/pAKT/XIAP signaling axis. Importantly, studies of patient samples indicate that expression of miR-520g/miR-587 correlates with chemoresistance in colorectal cancer, while expression of PPP2R1B is reversely correlated with chemoresistance in these patient samples. these findings indicate that the p53/miR-520g/p21 and miR-587/PPP2R1B/pAKT/XIAP signaling axis play important roles in mediating response to chemotherapy in colorectal cancer. A major implication of our studies is that inhibition of miR-520g/miR-587 or restoration of p21/PPP2R1B expression may have therpeutic potential to overcome drug resistance in colorectal cancer patients.

Combination Therapy as a Promising Strategy to Overcome Drug Resistance in Colorectal Cancer

Combination Therapy as a Promising Strategy to Overcome Drug Resistance in Colorectal Cancer
Author: Benardina Ndreshkjana
Publsiher: Unknown
Total Pages: 135
Release: 2019
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1155524899
Language: EN, FR, DE, ES & NL

Combination Therapy as a Promising Strategy to Overcome Drug Resistance in Colorectal Cancer Book Review:

Characterising Changes in Adhesion and Enzyme Activity Related to Drug Resistance in Colon Cancer Cells

Characterising Changes in Adhesion and Enzyme Activity Related to Drug Resistance in Colon Cancer Cells
Author: Heather Dekker
Publsiher: Unknown
Total Pages: 78
Release: 2018
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1122755467
Language: EN, FR, DE, ES & NL

Characterising Changes in Adhesion and Enzyme Activity Related to Drug Resistance in Colon Cancer Cells Book Review:

Metastatic colorectal cancer is often fatal, and drug resistance to chemotherapeutic agents is one of the primary contributing factors to this lethality. Drug resistance arises from exposure to chemotherapies, and it can be mediated through a variety of mechanisms. One of these mechanisms is alteration of enzymes within the cancer cells to affect the processing or removal of the drug. Carboxylesterase is an example of an enzyme that converts irinotecan, a drug used in metastatic colorectal cancer treatments, into the active metabolite SN-38. Carboxylesterase enzymes are found in high quantities in both the liver and intestinal cells. The presence of carboxylesterase in intestinal and liver cells is an important consideration in the processing of colorectal cancer treatments. Glutathione S-transferase is another enzyme that has been implicated in drug resistance because of its ability to conjugate reduced glutathione to xenobiotic substances, facilitating their removal. Additionally, drug resistance can affect the behaviours of cells. Drug-resistant cells can exhibit changes in their motility and aggressiveness compared to drug-sensitive cells. In this study I investigated cellular behavioural changes in SN-38-resistant colon cancer cells compared to their SN-38-sensitive counterparts. In addition to behavioural changes, I also sought to determine if elevations in carboxylesterase and glutathione S-transferase enzymes were contributing to the drug resistance in these colon cancer cells.

Mechanisms of Drug Resistance in Neoplastic Cells

Mechanisms of Drug Resistance in Neoplastic Cells
Author: Paul V. Woolley,Kenneth D. Tew
Publsiher: Elsevier
Total Pages: 416
Release: 2017-01-31
ISBN 10: 1483220753
ISBN 13: 9781483220758
Language: EN, FR, DE, ES & NL

Mechanisms of Drug Resistance in Neoplastic Cells Book Review:

Bristol-Myers Cancer Symposia, Volume 9: Mechanisms of Drug Resistance in Neoplastic Cells provides information on both basic scientific and clinical studies on the causes and implications of tumor cell resistance to common antineoplastic agents. The book describes the colon cancer as a model for resistance to antineoplastic drugs; mathematical modeling of drug resistance; and the mechanism of induced gene amplification in mammalian cells. The text also discusses the cellular concomitants of multidrug resistance; resistance to alkylating agents; and the phosphoprotein and protein kinase C changes in human multidrug-resistant cancer cells. Novel drugs that affect glutathione metabolism; the regulation of genes encoding drug-metabolizing enzymes in normal and preneoplastic tissues; and the relevance of glutathione S-transferases to anticancer drug resistance are also considered. The book further tackles the cellular resistance to cyclophosphamide; the preclinical and clinical experiences with drug combinations designed to inhibit DNA repair in resistant human tumor cells; and the modification of the cytotoxicity of DNA-directed chemotherapeutic agents by polyamine depletion. The text also demonstrates multidrug resistance and the circumvention of resistance. Oncologists, molecular biologists, biochemists, geneticists, and pharmacologists will find the book invaluable.

Oncoimmunology

Oncoimmunology
Author: Laurence Zitvogel,Guido Kroemer
Publsiher: Springer
Total Pages: 724
Release: 2017-12-13
ISBN 10: 3319624318
ISBN 13: 9783319624310
Language: EN, FR, DE, ES & NL

Oncoimmunology Book Review:

In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.

Delivery of Fluorouracil and SiRNA by Mesoporous Silica Nanoparticles to Drug Resistant Colorectal Cancer

Delivery of Fluorouracil and SiRNA by Mesoporous Silica Nanoparticles to Drug Resistant Colorectal Cancer
Author: Lijue Chen
Publsiher: Unknown
Total Pages: 183
Release: 2015
ISBN 10: 1928374650XXX
ISBN 13: OCLC:959799662
Language: EN, FR, DE, ES & NL

Delivery of Fluorouracil and SiRNA by Mesoporous Silica Nanoparticles to Drug Resistant Colorectal Cancer Book Review:

Mesoporous silica nanoparticle based drug and gene delivery system was developed to overcome the acquired drug resistance in colorectal cancer by targeted delivery of anti-cancer drug in the cytoplasm of the cancer cells and silencing the gene expression related to drug resistance.

Mathematical Modeling of Drug Resistance Due to KRAS Mutation in Colorectal Cancer

Mathematical Modeling of Drug Resistance Due to KRAS Mutation in Colorectal Cancer
Author: Anonim
Publsiher: Unknown
Total Pages: 135
Release: 2016
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1052078385
Language: EN, FR, DE, ES & NL

Mathematical Modeling of Drug Resistance Due to KRAS Mutation in Colorectal Cancer Book Review:

Cancer Drug Resistance

Cancer Drug Resistance
Author: Beverly A. Teicher
Publsiher: Springer Science & Business Media
Total Pages: 617
Release: 2007-11-09
ISBN 10: 1597450359
ISBN 13: 9781597450355
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Book Review:

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Polymorphism and Expression of Drug Resistance Genes in Colorectal Cancer Patients Given Adjuvant Folfox 4 Chemotheraphy

Polymorphism and Expression of Drug Resistance Genes in Colorectal Cancer Patients Given Adjuvant Folfox 4 Chemotheraphy
Author: Mojgan Mirakhrli
Publsiher: Unknown
Total Pages: 480
Release: 2011
ISBN 10: 1928374650XXX
ISBN 13: OCLC:975156701
Language: EN, FR, DE, ES & NL

Polymorphism and Expression of Drug Resistance Genes in Colorectal Cancer Patients Given Adjuvant Folfox 4 Chemotheraphy Book Review:

The Role of E cadherin in Colon Cancer Drug Resistance

The Role of E cadherin in Colon Cancer Drug Resistance
Author: Lynn Murray
Publsiher: Unknown
Total Pages: 226
Release: 2010
ISBN 10: 1928374650XXX
ISBN 13: OCLC:667166088
Language: EN, FR, DE, ES & NL

The Role of E cadherin in Colon Cancer Drug Resistance Book Review:

Drug Resistance in Oncology

Drug Resistance in Oncology
Author: S. Bernal
Publsiher: CRC Press
Total Pages: 416
Release: 1997-08-21
ISBN 10: 9781420002096
ISBN 13: 1420002090
Language: EN, FR, DE, ES & NL

Drug Resistance in Oncology Book Review:

This timely new reference integrates the latest clinical results and laboratory studies on the resistance of specific cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon cancer as well as hematological malignancies.

Non Canonical Pathways Induced Drug Resistance in Musashi 1 Positive Colorectal Cancer Stem Cell Lineages

Non Canonical Pathways Induced Drug Resistance in Musashi 1 Positive Colorectal Cancer Stem Cell Lineages
Author: Anonim
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1076840249
Language: EN, FR, DE, ES & NL

Non Canonical Pathways Induced Drug Resistance in Musashi 1 Positive Colorectal Cancer Stem Cell Lineages Book Review:

Colorectal Cancer

Colorectal Cancer
Author: Luis Rodrigo
Publsiher: BoD – Books on Demand
Total Pages: 440
Release: 2016-09-07
ISBN 10: 9535125443
ISBN 13: 9789535125440
Language: EN, FR, DE, ES & NL

Colorectal Cancer Book Review:

Colorectal cancer (CRC) is a major health problem because it represents around 10% of all cancers and achieves a worldwide estimate of 1.4 million newly diagnosed cases annually, resulting in approximately 700,000 deaths. Approximately 19-31% of patients present liver metastases. At diagnosis, a further 23-38% will develop extra-hepatic disease. Over the past decade, the widespread use of modern chemotherapeutic and biological agents, combined with laparoscopic surgical techniques, has improved the prognosis of metastatic CRC. A better understanding of the biology of the tumor, along with high efficiency of diagnostic and therapeutic methods, as well as the spread of screening programs, will improve the survival of the CRC patients in the near future.

The Roles of MLH1 and MSH2 in Growth and Drug Resistance in Human Colorectal Cancer Cells

The Roles of MLH1 and MSH2 in Growth and Drug Resistance in Human Colorectal Cancer Cells
Author: Amanda Barber
Publsiher: Unknown
Total Pages: 135
Release: 2012
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1032902669
Language: EN, FR, DE, ES & NL

The Roles of MLH1 and MSH2 in Growth and Drug Resistance in Human Colorectal Cancer Cells Book Review:

Multidrug Resistance in Cancer Pharmacological Strategies from Basic Research to Clinical Issues

 Multidrug Resistance in Cancer  Pharmacological Strategies from Basic Research to Clinical Issues
Author: Stefania Nobili,Enrico Mini,Chiara Riganti
Publsiher: Unknown
Total Pages: 135
Release: 2015-07-06
ISBN 10: 2889196151
ISBN 13: 9782889196159
Language: EN, FR, DE, ES & NL

Multidrug Resistance in Cancer Pharmacological Strategies from Basic Research to Clinical Issues Book Review:

More than 40 years ago, the observation that doxorubicin-resistant tumor cells were cross-resistant to several structurally different anticancer agents was the first step in the discovery of P-glycoprotein (P-gp). P-gp belongs to the superfamily of ATP-binding cassette (ABC) transporters;its overexpression has become a therapeutic target for overcoming multidrug resistance in tumors. However, P-gp is also expressed in cells of normal tissues where it plays a physiological role, by protecting them from the toxic effects of xenobiotics. Also, ABCB1 gene polymorphisms may influence the response to anticancer drugs substrate of P-gp. Several strategies to overcome P-gp tumor drug resistance have been suggested. P-gp 'circumvention’ is the most explored and is based on the coadministration of anticancer agents and pump inhibitors (P-gp modulators). Despite the positive findings obtained in preclinical studies, results of clinical trials are not yet successful and clinical research is still ongoing. Other investigational approaches have been studied (e.g. P-gp targeting antibodies, use of antisense strategies or transcriptional regulators targeting ABCB1 gene expression) but their use is still circumscribed to the preclinical setting. A further approach is represented by the encapsulation of P-gp substrate anticancer drugs into liposomes or nanoparticles. This strategy has shown higher efficacy in tumor previously treated with the free drug. The reasons explaining the increased efficacy of liposomal/nanoparticle-based drugs in Pgp-overexpressing tumors include the coating with specific surfactants, the composition changes in the plasma membrane microdomains where P-gp is embedded, the direct impairment of P-gp catalytic mechanisms exerted by specific component of the liposomal shell, but are not yet fully understood. A second strategy to overcome P-gp tumor drug resistance is represented by exploiting the P-gp presence. Actually, P-gp-overexpressing cells show increased sensitivity (collateral sensitivity) to some drugs (e.g. verapamil, narcotic analgesics) and to some investigational compounds (e.g. NSC73306). P-gp-overexpressing cell are hypersensitive to reactive oxygen species, to agents perturbing the energetic metabolic pathways, changing the membrane compositions, reducing the efflux of endogenous toxic catabolites. However, the mechanisms explaining collateral sensitivity have not been fully elucidated. Another approach to exploit P-gp is represented by ABCB1 gene transfer to transform bone marrow progenitor cells into a drug resistant state which may allow conventional or higher doses of anticancer drug substrates of P-gp to be administered safely after transplantation. More recently the development and introduction in the clinics of anticancer drugs which are not substrates of P-gp (e.g. new microtubule modulators, topoisomerase inhibitors) has provided a new and promising strategy to overcome P-gp tumor drug resistance (P-gp 'evasion'). This ‘research topic’ issue aims at exploding the above mentioned matters, in particular by: -retracing the history of the first researches on P-gp - describing the physiological role of P-gp - describing the molecular basis, structural features and mechanism of action of P-gp - describing diagnostic laboratory methods useful to determine the expression of P-gp and its transporter function - describing strategies to overcome tumor drug resistance due to P-gp and other ABC transporters - indicating novel approaches to overcome P-gp multidrug resistance, ranging from basic research studies to pre-clinical/clinical studies.